Havrix 1440 Adult/Havrix 720 Junior Dosage/Direction for Use

Posology: Primary vaccination: Adults from age 19 years and onwards: A single dose of Havrix 1440 Adult (1.0 ml suspension) is used for primary immunisation.
Children and adolescents from 1 year up to and including 18 years of age: A single dose of Havrix 720 Junior (0.5 ml suspension) is used for primary immunisation.
Booster vaccination: After primary vaccination with either Havrix 1440 Adult or Havrix 720 Junior, a booster dose is recommended in order to ensure long term protection. This booster dose should be given at any time between 6 months and 5 years, but preferably between 6 and 12 months after the primary dose (see Pharmacology: Pharmacodynamics under Actions).
Method of administration: Havrix is for intramuscular administration. The vaccine should be injected in the deltoid region in adults and children, in the antero-lateral part of the thigh in young children.
The vaccine should not be administered in the gluteal region.
The vaccine should not be administered subcutaneously/intradermally since administration by these routes may result in a less than optimal anti-HAV antibody response.
Havrix should under no circumstances be administered intravascularly.
Havrix should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects. Firm pressure should be applied to the injection site (without rubbing) for at least two minutes.